Skip to main content
. 2022 Nov 8;12:19020. doi: 10.1038/s41598-022-21317-x

Table 1.

Demographic and clinical characteristics of samples collected from SARS-CoV-2 infected cohort (n = 127), vaccinated cohort (n = 121), and controls (n = 70).

SARS-CoV-2 infected patients COVID-19 vaccinated individuals Pre-pandemic controls
Median age in years (IQR) 35.0 (27.0–43.5) 35.0 (25.5–44.5) 43.0 (37.0–51.0)
Gender
Female 20 (12.5) 68 (41.7) 3 (4.3)
Male 137 (85.6) 82 (50.3) 67 (95.7)
Not determined 3 (1.9) 13 (8.0)
Disease status
Symptomatic 56 (35.0)
Asymptomatic 90 (56.3)
Not determined 14 (8.8)
Vaccine type
Pfizer (BNT162b2) 97 (80.2)
Moderna (mRNA-1273) 24 (19.8)
Median days of sampling (IQR)a 46 (20–163) 63 (35–114)
Total 160 163 70

aMedian days of sampling post symptoms onset or RT-PCR positive test for SARS-CoV-2 infected cohort or post-second dose administration for the vaccinated cohort. SARS-CoV-2: severe acute respiratory syndrome virus 2, COVID-19: Coronavirus Disease 2019.

IQR interquartile range.

HHS Vulnerability Disclosure